| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f9a36328274867f46f8fc1fb9c868703 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5025 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate |
2021-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64cc246ae2987f6d76c0146dec6de85b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5aa5d0f23fbbec2ae4b50bc5ae93e08c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_797f375770582b569cc88f55f20cee26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb957a6a3ceedd50f2e7228e903fae9c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a85cbb8e0f94c34cd82d7a72abe2f9df
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2293ddbf7d5e664dc143e2701ac5c6f6 |
| publicationDate |
2021-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-3171441-A1 |
| titleOfInvention |
Naphthyridine and pyrido[3,4-c]pyridazine derivatives as gabaa .alpha_5.receptor modulators |
| abstract |
The present invention provides compounds of formula (I) and/or salts thereof and/or biologically active metabolites thereof and/or prodrugs thereof and/or solvates thereof and/or hydrates thereof and/or polymorphs thereof having affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 and act as GABAA ?5 positive allosteric modulators, thereby useful in the treatment or prevention of diseases related to the GABAA ?5 receptor, process for the preparation and intermediates of the preparation process thereof, pharmaceutical compositions comprising them alone or in combination with one or more other active ingredients and their use as medicaments. |
| priorityDate |
2020-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |